Quantcast

Daily Archives: June 2, 2007

Genentech (DNA): When Good News Is Bad

Genentech (DNA) announced that a new study uncovered that fact that its Avastin cancer drug can improve survival among people with severe lung cancer when it is added to other ...
Read Full Story »

GE (GE): The Bear Case

Barron's writes that GE's (GE) stock, which has been trading in the mid-$30s could go to $50. The magazine's article is fairly convincing. The company has sold off dogs like ...
Read Full Story »

The Thugs At GlaxoSmithKline (GSK)

After bad-mouthing research attacking its diabetes drug Avandia, word now comes from The New York Times that GlaxoSmithKline (GSK) attempted to intimidate a well-known diabetes researcher, Dr. John Buse. The ...
Read Full Story »

Harry Potter, The Stock Investor (SCHL)

Scholastic Corp. (SCHL-NASDAQ) made an announcement after Friday's close that the company was starting a $200 million accelerated share buyback plan via Deutsche Bank. The company expects to repurchase an ...
Read Full Story »

Cramer Thinks Navteq Could Get a Bid

Last night on CNBC's Mad Money, Jim Cramer had an interesting thought regarding merger rumors and speculation.  it was his 'Speculation Friday" after all.  He surmized that Navteq Corp. (NVT-NYSE) ...
Read Full Story »